

X-11704

-2-

5. The compound of [any of] Claim[s 1-] 4 wherein  $R^2$  is  $C=O$ .
6. The compound of [any of] Claim[s 1-] 5 wherein  $R^3$  is  $Ar^3$ .
7. The compound of [any of] Claim[s 1-] 6 wherein  $Ar^3$  is 4-fluorophenyl.
8. The compound of [any of] Claim[s 1-6] 7 wherein  $Ar^3$  is 4-fluorophenyl additionally mono- or disubstituted.
9. The compound of [any of] Claim[s 1-6] 8 wherein  $Ar^3$  is selected from the group consisting of 2-iodo-4-fluorophenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-difluorophenyl, and 2-methyl-4-fluorophenyl, and 2,4,6-trifluorophenyl.

---


13. The method according to [either of] Claim[s] 11 [or Claim 12] where the mammal is a human.

---

16. The process [of any] of Claim[s] 14 [-15] wherein the source of the protecting group of step a) is trifluoroacetic anhydride.
17. The process [of any] of Claim[s] 14 [-16] wherein the source of the nitronium ion is ammonium nitrate.
18. (New Claim) The process of any of Claim 16 wherein the source of the nitronium ion is ammonium nitrate.
19. (New Claim) The method according to Claim 12 where the mammal is a human.
20. (New Claim) A method for treating migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I:

X-11704

-3-



I;

or a pharmaceutical acid addition salt thereof, where;

A is hydrogen, halo, -OR<sup>4</sup>, NH<sub>2</sub>, or -CF<sub>3</sub>;

R is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl)-Ar<sup>1</sup>;

R<sup>1</sup> is -NH-R<sup>2</sup>-R<sup>3</sup>, hydroxy, -OSO<sub>2</sub>Ar<sup>2</sup>, or NH<sub>2</sub>;

Ar, Ar<sup>1</sup>, Ar<sup>2</sup>, Ar<sup>3</sup>, and Ar<sup>4</sup> are an optionally substituted phenyl or optionally substituted heteroaryl;

R<sup>2</sup> is -CO-, -CS-, or -SO<sub>2</sub>-;

R<sup>3</sup> is hydrogen, optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, Ar<sup>3</sup>, -NR<sup>5</sup>R<sup>6</sup>, or OR<sup>5</sup>; provided

R<sup>3</sup> is not hydrogen if R<sup>2</sup> is either -CS- or -SO<sub>2</sub>-;

R<sup>4</sup> is hydrogen, optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, or Ar; and

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl, or Ar<sup>4</sup>; or R<sup>6</sup> and R<sup>5</sup> combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

21. (New Claim) The method according to Claim 20 where the mammal is a human.

22. (New Claim) The compound of Claim 5 where A is hydrogen and R is methyl.

23. (New Claim) The compound of Claim 6 where A is hydrogen and R is methyl.